Treatment of HMGB1-mediated inflammation
Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
1. A method of treating high-mobility group box protein B1 (HMGB1)-mediated inflammation in a subject, by administering a therapeutically effective amount of P5779 to the subject in need thereof, wherein P5779 is the tetrapeptide FSSE (SEQ ID NO: 1) and HMGB1 is the HMGB1 disulfide isoform.
2. The method of claim 1 , wherein the HMGB1-mediated inflammation is caused by infection.
3. The method of claim 2 , wherein the HMGB1-mediated inflammation is caused by viral infection.
4. The method of claim 3 , wherein the HMGB1-mediated inflammation is caused by influenza infection.
5. The method of claim 3 , further comprising administering an antiviral agent to the subject.
6. The method of claim 5 , wherein the antiviral agent is oseltamivir.
7. The method of claim 2 , wherein the HMGB1-mediated inflammation is caused by bacterial infection.
8. The method of claim 2 , wherein P5779 is administered after the onset of infection.
9. The method of claim 1 , wherein the HMGB1-mediated inflammation is caused by sterile injury.
10. The method of claim 1 , wherein the HMGB1-mediated inflammation is caused by acetaminophen toxicity.
11. The method of claim 1 , wherein the subject is human.
12. The method of claim 1 , wherein P5779 is administered in a pharmaceutically acceptable carrier.